JP2002504491A5 - - Google Patents

Download PDF

Info

Publication number
JP2002504491A5
JP2002504491A5 JP2000532434A JP2000532434A JP2002504491A5 JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5 JP 2000532434 A JP2000532434 A JP 2000532434A JP 2000532434 A JP2000532434 A JP 2000532434A JP 2002504491 A5 JP2002504491 A5 JP 2002504491A5
Authority
JP
Japan
Prior art keywords
peptide analog
residue
residues
chain
human insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000532434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002504491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/003915 external-priority patent/WO1999042482A1/en
Publication of JP2002504491A publication Critical patent/JP2002504491A/ja
Publication of JP2002504491A5 publication Critical patent/JP2002504491A5/ja
Pending legal-status Critical Current

Links

JP2000532434A 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法 Pending JP2002504491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
US09/028,156 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (2)

Publication Number Publication Date
JP2002504491A JP2002504491A (ja) 2002-02-12
JP2002504491A5 true JP2002504491A5 (https=) 2006-03-23

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000532434A Pending JP2002504491A (ja) 1998-02-23 1999-02-23 インスリンのペプチドアナログを使用した糖尿病の処置のための方法

Country Status (20)

Country Link
US (1) US6197926B1 (https=)
EP (1) EP1056776A1 (https=)
JP (1) JP2002504491A (https=)
KR (1) KR20010041238A (https=)
CN (1) CN1241942C (https=)
AP (1) AP2000001888A0 (https=)
AU (1) AU741037B2 (https=)
BR (1) BR9908178A (https=)
CA (1) CA2321929A1 (https=)
EA (1) EA003944B1 (https=)
HU (1) HUP0100928A3 (https=)
ID (1) ID26788A (https=)
IL (1) IL137904A0 (https=)
NO (1) NO20004198L (https=)
NZ (1) NZ506447A (https=)
OA (1) OA11453A (https=)
PL (1) PL342517A1 (https=)
SK (1) SK12412000A3 (https=)
TR (1) TR200003048T2 (https=)
WO (1) WO1999042482A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
AU5984701A (en) * 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
ZA200502613B (en) 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CN1798569A (zh) * 2003-06-02 2006-07-05 莫西亚药物公司 用于治疗1型糖尿病的治疗性疫苗组合物
CA2575604A1 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2010080606A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
EP2496255A4 (en) 2009-11-05 2014-03-26 Mercia Pharma Inc ADJUVATED INFLUENZA VACCINE IN NANOPARTICLE FORM
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation アミド系インスリンプロドラッグ
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2016049174A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Lipidated amide-based insulin prodrugs
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Similar Documents

Publication Publication Date Title
JP2002504491A5 (https=)
EP0528312A3 (en) Cyclic peptides and use thereof
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2003264514A8 (en) Wt1 substitution peptides
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
WO2001049314A3 (en) Glp-2 formulations
JP2002509854A5 (https=)
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
MXPA05002991A (es) Analogos de ghrh.
KR930009591A (ko) 트리-아르기닌 인슐린
DK0482013T3 (da) Ikke-glycolyserede humant interleukin-3 analoge proteiner
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
AU2002330289A1 (en) Preparation of a therapeutic composition
WO2004009625A3 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES
GR3031927T3 (en) Cysteine depleted il-6 muteins
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
DE69636052D1 (de) Mpl-liganden analoga
WO2003099849A3 (en) Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
JP2004505616A5 (https=)
ATE371737T1 (de) Proteaseresistente flint-analoge
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
AU1464488A (en) Human rhinovirus peptides
MY120083A (en) Process for the preparation of cyclo(asp-dphe-nmeval-arg-gly)